Moreover, the fact that in vivo BARD1 isoforms are expressed and significantly down- regulated in many, but not all, AML patients undergoing Vorinostat administration, strongly supports the hypothesis that patients might benefit from a pre-selection based on expression of truncated BARD1 isoforms for a more effective epigenetic treatment. The gene discussed is BARD1; the disease is acute myeloid leukemia.